Proceedings of The Physiological Society

Europhysiology 2018 (London, UK) (2018) Proc Physiol Soc 41, PCB013

Poster Communications

Possible Effects Of Agomelatine On Human Heart Muscle Contractility: An In Vitro Experimental Study

Z. Solak Gormus1, R. Ozen Koca1, A. Koc3, H. Solak1, F. Taki1, S. Kutlu1, N. Gormus2

1. Physiology, Necmettin Erbakan University, Konya, Turkey. 2. Cardiovascular Surgery, Necmettin Erbakan University, Konya, Turkey. 3. Physiology, Hitit University Faculty of Medicine, Corum, Turkey.


AIM The novel antidepressant agomelatine is an agonist of melatonin receptors (MT1 and MT2). This drug has also serotonin 2c receptor antagonism properties. The effect of agomelatine on cardiovascular system is not clear so far. The aim of the present study is to investigate the effect of agomelatine on human atrium contraction. METHODS: Human atrium tissues (n=30) were taken from patients who underwent coronary bypass surgery. The patients' ages were between 47 to 72. All tissues were placed in organ baths containing Krebs solution, thermoregulated at 37 0C and aerated (95 % O2 and 5% CO2). Changes in isometric tensions were recorded using a four channel force displacement transducer. All tissues washed for 3 hours in order to diminish the effects of anaesthetic agents. Adrenaline (10-1 M) was administered in tissue cabs to induce isometric contractions. Contraction with measurements were used as contraction parameters. Cumulative agomelatine (10-9 to 10-4) doses were added in organ baths. The contractions were recorded accordingly. Friedman and Kruskal Wallis tests were used for statistical evaluation. RESULTS AND CONCLUSIONS: Inhibition of contraction was statistically significant in the last cumulative dose of agomelatine (10-4 M ) (p<0.05) following the administration of adrenaline. Results of this study showed that agomelatine may cause negative inotropic effects at certain high doses on human atrium muscle. Further studies are needed to clarify the mechanism(s) of effect of agomelatine. These results suggest that agomelatine may have beneficial effects on treatment of cardiovascular diseases.

Where applicable, experiments conform with Society ethical requirements